|drug702||Cardiac CT Wiki||1.00|
|drug1161||Electrocardiogram (ECG) Wiki||1.00|
|drug488||Blood samples Wiki||0.58|
|D016171||Torsades de Pointes NIH||1.00|
|D054537||Atrioventricular Block NIH||1.00|
There is one clinical trial.
Our understanding of the clinical manifestations of COVID-19 is growing on a daily basis and there is evidence that increased age, cardiovascular risk factors and cardiac comorbidity are strongly associated with poor outcomes. Furthermore, myocardial injury occurs and is associated with a much worse outcome and rapid increase in mortality. There have been several reports of myocarditis and heart failure following infection. The mechanisms of myocardial injury and its consequences are not well understood. In an ongoing peer-reviewed and funded study, the investigators are evaluating the use of magnetic resonance imaging (MRI) to characterise and to understand the mechanisms of heart failure and myocarditis. Following strong encouragement by the British Heart Foundation, the investigators now propose to extend this investigation to patients who have recovered from COVID-19 infection to understand the mechanisms of myocardial injury that they have experienced. Using gadolinium and manganese-enhanced MRI combined with Computed tomography coronary angiography (CTCA), the investigators will assess the mechanisms and direct impact of myocardial injury in patients who have recovered from COVID-19 infection. This will help the investigators understand how best to manage individuals who demonstrate evidence of myocardial injury and potentially provide insights that could lead to novel treatment interventions to reduce such injury and improve patient outcomes.
Description: Measure late gadolinium enhancementMeasure: MRI with gadolinium Time: 2 years
Description: Measure T1 values to calculate ECV (%)Measure: Extra-cellular volume (ECV) Time: 2 years
Description: Measure manganese uptakeMeasure: Manganese MRI Time: 2 years
Description: Measure degree of coronary diseaseMeasure: CTCA Time: 2 years
Description: measure troponin profile in patientsMeasure: Cardiac biomarkers Time: 2 years
Description: ECG RhythmMeasure: Electrocardiogram Time: 2 years
Description: ECG ST segmentMeasure: Electrocardiogram Time: 2 years
Description: ECG RateMeasure: Electrocardiogram Time: 2 years
Description: ECG T wave morphologyMeasure: Electrocardiogram Time: 2 years
Description: ECG QT intervalMeasure: Electrocardiogram Time: 2 years
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports